Free Trial
NASDAQ:GLMD

Galmed Pharmaceuticals (GLMD) Stock Price, News & Analysis

Galmed Pharmaceuticals logo
$1.34 -0.05 (-3.24%)
As of 03:33 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Galmed Pharmaceuticals Stock (NASDAQ:GLMD)

Key Stats

Today's Range
$1.26
$1.44
50-Day Range
$1.37
$2.33
52-Week Range
$1.15
$23.80
Volume
1.49 million shs
Average Volume
1.05 million shs
Market Capitalization
$2.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Galmed Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
35th Percentile Overall Score

GLMD MarketRank™: 

Galmed Pharmaceuticals scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Galmed Pharmaceuticals is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Galmed Pharmaceuticals is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Galmed Pharmaceuticals has a P/B Ratio of 0.13. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Galmed Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    2.11% of the float of Galmed Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Galmed Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Galmed Pharmaceuticals has recently decreased by 66.18%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Galmed Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Galmed Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.11% of the float of Galmed Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Galmed Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Galmed Pharmaceuticals has recently decreased by 66.18%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Galmed Pharmaceuticals has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Galmed Pharmaceuticals this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Galmed Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    19.80% of the stock of Galmed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    76.14% of the stock of Galmed Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Galmed Pharmaceuticals' insider trading history.
Receive GLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GLMD Stock News Headlines

Think you missed gold’s boom? Think again
If you've been watching gold's historic run and wondering if it's too late… I've got good news. Because there's a $15 fund tied directly to gold's surge that's still paying massive income… Up to 64% annually — with payouts every 30 days.tc pixel
See More Headlines

GLMD Stock Analysis - Frequently Asked Questions

Galmed Pharmaceuticals' stock was trading at $3.19 on January 1st, 2025. Since then, GLMD stock has decreased by 59.1% and is now trading at $1.3050.

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) released its earnings results on Thursday, August, 28th. The biopharmaceutical company reported $0.63 EPS for the quarter.

Shares of Galmed Pharmaceuticals reverse split on Monday, May 15th 2023.The 1-15 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Galmed Pharmaceuticals investors own include Viking Therapeutics (VKTX), OPKO Health (OPK), SCYNEXIS (SCYX), Bristol Myers Squibb (BMY), Plug Power (PLUG), Applied Genetic Technologies (AGTC) and Sorrento Therapeutics (SRNE).

Company Calendar

Today
8/28/2025
Last Earnings
8/28/2025
Next Earnings (Estimated)
11/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GLMD
CIK
1595353
Employees
20
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($16.66)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$7.52 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-32.21%
Return on Assets
-28.59%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.02
Quick Ratio
9.02

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.87 per share
Price / Book
0.13

Miscellaneous

Outstanding Shares
1,654,000
Free Float
1,327,000
Market Cap
$2.16 million
Optionable
Not Optionable
Beta
0.58

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:GLMD) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners